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GenDeR sIMIlARItIes AnD DIffeRenCes In oUtCoMes At 1-yeAR
The international literature indicates that men and women entering drug treatment differ in demographic characteristics, 
drug use histories, offending and psychosocial behaviour patterns. There are mixed findings on gender differences in 
treatment outcomes, with most large-scale studies showing no differences and other (smaller) studies favouring one 
gender over the other. To maximise the effectiveness of any treatment programme catering for both men and women, 
service providers must be aware of, and address, any gender-based variations. 
The aim of this paper is to determine whether any such variations exist among a cohort of opiate users in treatment in 
Ireland. To this end gender differences in the characteristics, problems and 1-year treatment outcomes of 285 opiate 
users who participated in the ROSIE Study (and completed interviews at the two time periods) are explored.
Key MessAGes
1. Results showed that although men and women started their 
ROSIE treatment episode at similar ages, they presented to 
treatment with different problems and characteristics. 
2. Women were more likely to be parents and to have additional 
responsibilities for childcare. 
3. Conversely men reported greater drug involvement, longer  
drug using careers and greater involvement with the criminal 
justice system. 
4. Despite different profiles of problems, men and women 
reported significant reduction in their drug use and offending 
behaviour at 1-year follow-up.
IntRoDUCtIon
Differences in addiction careers and patterns of drug use for women and 
men have frequently been reported in the literature. For example, it has been 
observed that women tend to start using alcohol and other drugs at a later 
age than men, and their boyfriend/partner or spouse often initiates them 
into use (Hser et al, 1987). Women report a shorter transition from drug use 
to addiction and generally enter treatment sooner than men (Grella & Joshi, 
1999; Acharyya & Zhang, 2003; Hernandez-Avila et al, 2004). 
In addition, there is accumulating evidence that the biological effects of drugs 
are not always the same for males and females (Acharyya & Zhang, 2003). 
For example, research suggests that there is a greater cardiovascular sensitivity 
to the effects of cocaine for women than for men (Lukas et al, 1996).
Women drug users have been found to face more problems related to 
child-rearing as they are usually the primary child-carer (Fiorentine et al, 
1997). They also tend to have limited incomes, education and job skills 
(Hser et al, 2003; Green et al, 2002). Other research has reported 
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IntRoDUCtIon (continued) 
significantly more psychiatric disorders, particularly affect 
disorders, among drug using women than men (Teesson et 
al, 2005). More specifically studies have found women have 
lower self-esteem, heightened anxiety, depression and self-
destructive behaviour (Greenfield et al, 2007).
Male drug users have been found to be more criminally 
involved than women, especially when it comes to drug 
dealing (Gossop et al, 2000). They are also more likely than 
their female counterparts to have been incarcerated and 
under legal supervision (e.g. on probation). 
Relatively few studies have examined treatment outcomes 
by gender. In the US, findings from the Treatment Outcome 
Prospective Study (TOPS) indicate that post-treatment 
outcomes were not predicted by gender, with the exception 
of employment (Hubbard et al, 1989). Similarly the Drug 
Abuse Treatment Outcome (DATOS) study (Acharyya & 
Zhang, 2003) found only minimal differences in outcomes 
between men and women in four drug treatment modalities 
(methadone, non-methadone outpatients, short-term 
inpatient & long-term residential). Another US study (Hser  
et al, 2003) found no overall gender difference in 1-year 
drug and alcohol treatment outcomes but did find gender-
specific baseline predictors of treatment outcomes. The UK 
outcome study NTORS revealed that despite pre-treatment 
differences between men and women, the variables on 
which they differed were not strongly or consistently related 
to outcomes (Stewart et al, 2003). 
Generally, findings from these large-scale outcome studies 
indicate similarities in outcomes between men and women 
despite differences in their characteristics and problems at 
intake to treatment.
Between 1998 and 2002 approximately 30% of the drug 
treatment population in Ireland were women (Long et al, 
2005) and as of November 2007 there were 2,604 women 
receiving methadone treatment (30% of the methadone 
population) (HSE, 2008). However, gender is often 
ignored in Irish research, or only treated as a demographic 
variable. Consequently, there is a dearth of research on the 
relationship between gender and drug use problems, how 
gender influences treatment seeking behaviour and referral 
into treatment, and whether there are gender differences in 
treatment outcomes. 
The gender differences in the characteristics and problems 
of drug users identified in the literature raise questions 
about the extent to which treatment services are able to 
meet the differing needs of men and women, and about 
possible differences in the relative effectiveness of treatment 
interventions. While it is beyond the scope of the ROSIE 
study to determine whether men and women have different 
treatment needs, gender differences in treatment intake 
characteristics and outcomes at 1-year will be explored  
in this paper.
MetHoDoloGy
The ROSIE Study is the first large-scale, prospective, multi-
site, drug treatment outcome study in Ireland. The primary 
aim of the study is to evaluate the effectiveness of treatment 
and other intervention strategies for opiate users.
Between September 2003 and July 2004, participants were 
recruited to the study and completed a comprehensive 
interview at service intake (or as soon as possible thereafter). 
These interviews were designed to obtain baseline data 
on drug use and other behaviours. As well as information 
on background and demographic characteristics, data were 
collected on patterns of drug use, living situation, education 
and training, income, offending behaviour and drug-related 
risk behaviour, along with an assessment of physical and 
mental health. Participants were re-interviewed at 1-year 
and 3-years after service intake. These follow-up interviews 
replicated many of the questions asked at intake interview 
focusing primarily on behaviour in the three months prior  
to interview. 
The study design did not include random allocation to 
treatment. A total of 44 agencies, providing approximately 
54 services participated in the ROSIE Study. Agencies were 
purposively sampled to reflect the known geographical 
spread of provision and range of services in Ireland. Four 
types of services were included; methadone maintenance 
(n=215; 53%), medically-supervised detoxification (n=81; 
20%), abstinence-based treatment (n=82; 20%) and 
needle-exchange (n=26; 7%).
stUDy PARtICIPAnts
A total of 404 participants completed ROSIE Study intake 
interviews; 378 were commencing treatment for their 
opiate use (excluding the 26 individuals recruited in needle-
exchange which is not considered treatment per se). Of 
these 378 participants 75% (n=285) completed 1-year 
follow-up interview; 209 (73%) men and 76 (27%) women. 
These 285 participants are the focus of this paper.
DAtA AnAlysIs
In order to explore gender based variations in the data 
several approaches to the analysis were undertaken.  
To determine whether there were gender differences in 
treatment intake demographic and lifetime characteristics 
of participants, independent t-tests were conducted for 
continuous variables and chi-square tests for categorical 
variables (table 1).
Paired t-test analyses were conducted within gender 
to determine treatment intake and 1-year follow-up 
comparisons in drug use and other key outcome variables. 
The p-values for these analyses are presented in table 2  
and table 3 along with the mean difference (in days) in  
the intake and follow-up frequency of each variable.
A general linear model for a repeated measures design 
with backward elimination was computed to explore further 
gender differences in treatment outcomes at 1-year. A total 

Authors: Dr Gemma Cox, Paul Kelly and Dr Catherine Comiskey
October 2008Findings 5 : Gender similarities and differences in outcomes at 1-year
of 13 outcome variables at 1-year covering outcomes in 
drug use, physical health, mental health, crime and social 
functioning were analysed. When modelling each of the  
13 outcome variables, 8 co-variates were controlled for, 
both for that variable’s individual effect on the outcome 
and its possible effect or interaction with other co-variates. 
The co-variates chosen to reflect key variables were gender, 
treatment intake modality, previous treatment, parent of child 
under 18 years, currently employed, health rating, prison 
history and finally the intake reading of the outcome variables 
being modelled at 1-year. 
Missing data were handled by excluding the cases from the 
particular analysis. All analysis was conducted using SPSS. 
Shaded cells (and/or p<0.05) in the Tables indicate statistical 
significance.
ResUlts
a) Gender differences in intake 
demographic and lifetime characteristics
table 1 shows that there were no statistically significant 
gender differences in the age profile at service intake or in 
the age at which participants left school. Women were more 
likely than men to report being parents (70% compared 
to 50.5% p<0.01); with over half the women (59%) 
having primary childcare responsibilities compared with 
only 15% of men (p<0.001). Although women (27%) 
were proportionately more likely than men (19%) to report 
living with a drug user, the difference was not statistically 
significant. 
Both men and women reported the use of a range of 
substances over their drug using careers, with fewer women 
than men having ever used non-prescribed methadone 
(80% compared to 90%, p<0.05) and cannabis (90% 
compared to 98.5% p<0.001). The age of first use of 
heroin and non-prescribed methadone was similar for men 
and women. However, men initiated the use of cocaine, 
benzodiazepines†, cannabis and alcohol at a significantly 
younger age than women. 
Analysis revealed that more men than women reported 
having an arrest history (81% compared to 58%, p<0.001). 
In addition, men (71%) were significantly more likely than 
women (34%) to have had a history of imprisonment 
(p<0.001). 
There were significant gender differences in treatment 
modality at intake interview among ROSIE study participants; 
women were proportionately more likely than men to 
be recruited to the ROSIE study from within methadone 
treatment (75% compared to 53%), and men were 
proportionately more likely than women to be recruited from 
within abstinence-based treatment (24% compared to 7%). 
(b) Gender differences in intake drug use 
and drug use outcomes at 1-year
table 1 shows that there were no significant gender 
differences in the reported use of the seven target drugs at 
treatment intake. However, men were proportionately more 
likely than women to have used heroin (81% compared 
to 74%) and cannabis (67% compared to 57%) in the 
preceding three months. Similar proportions of men (77%) 
and women (80%) reported polydrug use. In addition, there 
was no gender difference in reported injecting drug use.
Analysis also revealed that there were no statistically 
significant gender differences in the mean number of days 
participants reported the use of each of the seven target 
drugs at treatment intake. In other words, the frequency  
of use of all substances was similar for men and women  
(table 2).
Treatment intake and 1-year follow-up comparisons 
presented in table 2 show that there were significant 
reductions in the mean number of days men reported using 
all target drugs, except crack cocaine. For example, the mean 
difference in the number of heroin-using days at treatment 
intake and 1-year for men was 26.5 (days).
There was a significant reduction in the mean number 
of days women reported using heroin, methadone†, 
benzodiazepines† and cocaine. However, there were no 
statistically significant differences in the reported frequency  
of crack cocaine and cannabis use. Moreover, there was  
a slight, albeit non-significant, increase (as indicated by the 
minus sign) in the mean number of days women reported 
the use of alcohol at 1-year, when compared with use at 
treatment intake. 
Both men and women reported significant reductions in 
the frequency of injecting drug use. For example, the mean 
difference in the number of drug injecting days at intake and 
1-year was 20 days for women, and 14 days for men.
†  Non-prescribed.
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Table 1:  Pre-Treatment: Characteristics and Problems by Gender
Variable  % or Mean (sd)
 Male female
 (n=209)  (n=76) P value
Demographics	 	 	
 Age   
  18-25 years 39.7 44.7 ns
  26-35 years 53.1 42.1 
  36-45 years 4.8 10.5 
  > 45 years 2.4 2.6 
    
  Mean age  27.6 (5.9) 28.1 (6.8) ns
 Age left school 15.1 (1.8) 15.4 (1.5) ns
 Parent  50.5 70.0 <0.01
 Primary childcarer 15.2 59.4 <0.001
 a Homeless  7.8 9.5 ns
 a Living with drug user(s)  19.1 26.8 ns
b Drug	use	history	 	 	
 Heroin 99.0 98.7 ns
  Age first used 18.2 (4.0) 19.0 (5.9) ns
 Methadone (non-prescribed) 90.0 79.7 <0.05
  Age first used 20.6 (5.4) 21.0 (5.8) ns
 Cocaine  92.8 85.5 ns
  Age first used 18.9 (3.7) 22.1 (5.4) <0.001
 Benzodiazepines (non-prescribed) 88.9 82.9 ns
  Age first used 18.4 (4.5) 20.1 (5.8) <0.05
 Cannabis 98.5 90.0 <0.001
  Age first used 14.1 (2.9) 15.2 (4.1) <0.05
 Alcohol 93.3 93.0 ns
  Age first used 13.4 (2.4) 14.5 (2.3) <0.01
 Injecting drug use 75.8 76.3 ns
  Age first injected 20.6 (4.4) 21.1 (5.8) ns
b Drug	use	at	Treatment	Intake		 	 	
 Heroin  81.4 73.7 ns
 Methadone (non-prescribed) 45.4 47.4 ns
 Cocaine powder  44.5 44.7 ns
 Crack cocaine  16.7 15.8 ns
 Benzodiazepines (non-prescribed)  43.6 44.7 ns
 Cannabis 66.8 57.1 ns
 Alcohol  58.2 55.6 ns
 Polydrug use 76.6 80.3 ns
 Injecting drug use  42.0 43.4 ns
Criminal	history   
 Ever arrested 80.8 57.7 <0.001
 Ever in prison  71.2 33.8 <0.001
Offending	at	Treatment	Intake	   
 b Acquisitive crime 30.3 33.8 ns
 b Drug selling/dealing 31.4 27.3 ns
 a Legal problems 52.5 30.6 <0.001
Treatment	history   
 Previous drug treatment 88.9 82.9 ns
  Age first treatment 21.2 (5.6) 21.8 (6.5) ns
 Previously on methadone 55.8 61.8 ns
RosIE	treatment	modality   
 Methadone Maintenance/Reduction 52.6 75.0 <0.001
 Detoxification 23.0 18.4 
 Abstinence-based  24.4 6.6
a Refers to circumstances at Intake interview. 
b Refers to behaviour in the three months prior to intake interview.
 A P	value of less than <0.05 denotes a statistically significant gender difference. 
	 ns denotes no statistical significance.
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Table 2:  Drug Use Outcomes: Intake differences 
by gender and changes at 1-year within gender
Intake - follow-up 
difference in mean 
number of days
Intake 
gender 
differences
Male
(n=209)
female
(n=76)
Drugs Mean days Mean days P value
Heroin 26.5 30.9 ns
1Methadone 7.8 13.4 ns
2Benzodiazepines 11.9 6.5 ns
Cocaine 2.9 7.4 ns
Crack 0.8 3.4 ns
Cannabis 10.2 6.3 ns
Alcohol 5.2 -0.2 ns
Injecting drug use 13.9 19.8 ns
1 Refers to non-prescribed methadone
2 Refers to non-prescribed benzodiazepines
* Shaded cell indicates statisitcally significant difference between 
intake and 1-year within gender 
ns	denotes not statistically significant
c) Gender differences in intake offending  
and crime outcomes at 1-year 
Comparisons by gender of pre-treatment involvement 
in crime are presented in table 1. Women were 
proportionately more likely than men to report having 
committed an acquisitive crime (34% compared to 30%) 
and men were proportionately more likely than women to 
report having dealt drugs (31% compared to 27%). Although 
the gender differences in reported involvement in acquisitive 
crime and drug selling were not statistically significant, men  
were significantly more likely than women to report having 
legal problems at treatment intake (52.5% compared to 
31%, p<0.001).
table 3 illustrates that not only were men more likely to 
report drug dealing than women at treatment intake, they 
reported dealing drugs on significantly more (mean) days 
than women (14.7 days versus 7.2 days). Looking at the 
frequency of individual acquisitive crimes (e.g. theft from 
a person, theft of a vehicle, theft from a vehicle) analysis 
revealed that the only gender difference was in the  
frequency of shop-lifting. Women reported committing  
theft from a shop/commercial property on significantly  
more (mean) days than men at treatment intake  
(15.8 days compared to 2 days).
Treatment intake and 1-year comparisons show that there 
were significant reductions in the mean number of days 
women reported both drug dealing and shop lifting. Among 
men there was a significant reduction in the mean number  
of drug dealing days at 1-year.
Table 3:  Crime and Health Outcomes: Intake 
differences by gender and changes at 1-year  
within gender
Intake - follow-up 
difference in mean 
number of days
Intake 
gender 
differences
Male
(n=209)
female
(n=76)
Crime Mean days Mean days P value
Drug selling 9.3 6.6 <0.05
Theft from shop/
commercial property
1.3 10.3 <0.01
Health
Suddenly scared for 
no reason
6.6 7.7 ns
Feeling fearful 8.2 0.1 ns
Feeling hopeless 
about future 
8.6 7.2 ns
No interest in things 6.2 4.5 ns
Poor appetite 12.3 12.8 ns
Nausea -1.6 2.5 ns
Stomach pains 1.8 -3.6 ns
Stayed overnight in 
hospital
0.5 -0.2 ns
Attended GP -1.2 -1.4 ns
 A P	value of less than <0.05 denotes a statistically significant 
gender difference 
ns	denotes no statistical significance
(d) Gender differences in intake health 
symptoms and health outcomes at 1-year
Analysis revealed that there were no significant gender differences 
in the reported frequencies (measured in mean days) of the 
individual health symptoms or in the frequency of reported 
contact with health services at treatment intake (table 3).
Treatment intake and 1-year comparisons showed that there 
were significant reductions in the mean number of days 
men experienced two anxiety-related symptoms (suddenly 
scared for no reason, and feeling fearful) and one depressive 
symptom (feeling hopeless about the future). Although there 
were reductions in reported mental health symptoms among 
women, none were statistically significant. 
In terms of physical health both men and women reported 
a significant reduction in the mean number of days they 
experienced poor appetites. Although not statistically 
significant there was an increase in the mean number 
of days men reported experiencing nausea and women 
reported experiencing stomach pains at 1-year. Finally, 
women reported a significant increase (as indicated by the 
minus sign) in the mean number of days they had contact 
with a general practitioner at 1-year.
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In spite of 13 outcome variables being modelled and 
controlling for co-variates only two variables demonstrated 
significant gender effects, cannabis use and drug dealing.
Firstly, the use of cannabis at 1-year demonstrated significant 
gender by treatment modality effects. Men recruited within 
the methadone modality used cannabis on significantly more 
mean days than women (44.4 compared to 28.3) at 1-year. 
Conversely, women used cannabis on significantly more mean 
days than men within the detoxification modality (30 compared 
to 20.5) and the abstinence modality (5.6 compared to 0.05). 
Secondly, drug dealing at 1-year demonstrated a significant 
gender effect; men reported dealing drugs on significantly more 
mean days than women (5.6 compared to 0.05).
sUMMARy AnD IMPlICAtIons
The data presented in this paper examine gender differences 
among a sample of opiate users at treatment intake and  
1-year follow-up. The findings and their implications are 
summarised below.
Do women present to treatment with a 
different profile of problems than men?
Many of the findings are consistent with international research 
which shows that women present to treatment with a different 
profile of problems to men (Stewart et al, 2003; Chatham et al, 
1999; Powis et al, 1996). 
The women on the ROSIE study were significantly more likely 
than the men to be parents, and to have additional responsibility 
for childcare. Childcare responsibilities often emerge in the 
literature as a barrier to women accessing treatment. However, 
there is evidence to support the contrary; rather than inhibiting 
treatment seeking, a major motivating force for women to enter 
treatment can be concern over their children’s welfare (Klein, 
1996; Swift et al, 1996). That said, the most important obstacle 
to women actually entering treatment has been found to be the 
lack of childcare facilities within treatment services (Rosenbaum 
& Murphy, 1981). It is important to encourage women drug 
users with children to enter treatment. Consequently, drug 
treatment programmes must accommodate women’s childcare 
needs, adequately address parenting issues and provide 
advice and information on safe storage of drugs and injecting 
paraphernalia. Where the type or extent of these needs exceeds 
the capacity of any one agency to provide a comprehensive 
response, collaborative links between agencies should be 
established and strengthened. 
As in other research, the men on the ROSIE study reported 
greater drug involvement and longer drug using careers than 
the women; they initiated cocaine, benzodiazepines†, cannabis 
and alcohol use at a significantly younger age than their female 
counterparts. Although women had shorter drug using careers 
than the men, there were no significant gender differences in 
pre-treatment drug use. This may indicate that women progress 
to problematic drug use and dependency quicker than men. 
Given their shorter drug using careers, it is worrying that the 
women were as likely as the men to report the use of all target 
drugs in the preceding three months. Moreover, there was no 
gender difference in the frequency of reported use (measured 
in mean days) of these drugs. The women were also as likely as 
the men to be injecting drug users and polydrug users. 
Similar to the findings of other studies the men on the ROSIE 
study were more likely to have been in prison, to have been 
arrested and to have had legal problems at treatment intake 
(Stewart et al, 2003). Men’s involvement in the criminal 
justice system may influence their routes into treatment and 
their motivation for accessing treatment. In addition, gender 
differences were observed in levels of involvement in the two 
pre-treatment crime variables; men dealt drugs on more days 
than women, and women committed theft from a shop on 
more days than men. These findings have been replicated in 
the international research.
Are there gender differences in treatment 
outcomes? 
Both the men and the women on the ROSIE study showed 
substantial reductions in drug use at 1-year; significant 
reductions in the frequency of use (measured in mean 
days) of heroin, methadone†, benzodiazepines† and cocaine 
were observed. In addition, the mean number of days men 
and women reported injecting drug use reduced at 1-year. 
However, some gender differences were observed in drug use 
outcomes. Although there were reductions in cannabis and 
crack use among women, the differences were not statistically 
significant. In addition analysis revealed that women recruited 
within both the detoxification and the abstinence-based 
modalities used cannabis on significantly more mean days 
than men at 1-year. 
On the other hand, although there were significant reductions 
in cannabis use among men, within the methadone modality 
men used cannabis on more mean days than women at 
1-year. Research suggests that cannabis use rates among 
methadone-maintained individuals are high (Calsyn & Saxon, 
1999). The available evidence suggests that it only marginally 
affects treatment outcomes (Seivewright, 2003) demonstrating 
a weak association with psychosocial problems at post-
treatment follow-up (Epstein & Preston, 2003). However, 
research does indicate that opiate-dependent cannabis users 
are more likely to be involved in drug dealing than non-
cannabis users (Budney et al, 1998).
There was a gender difference in outcomes for alcohol 
consumption. Although similar proportions of men (58%) and 
women (56%) reported alcohol use at treatment intake and 
there was no gender difference in the frequency of alcohol  
use, women’s reported alcohol use increased slightly at  
1-year. In contrast there was a significant reduction in the mean 
number of days men reported drinking. Alcohol consumption 
has important health implications for drug users. High rates 
of hepatitis B and C among injecting drug users is known to 
elevate the risk to health of excessive drinking. Alcohol also 
increases the risk of overdose when used with other sedative 
drugs (Gossop et al, 2002) including methadone (Man et 
al, 2004). This is of particular concern as women in the 
ROSIE study were more likely to be in methadone treatment 
and research shows that the threshold for fatal methadone 
overdose is lowered by alcohol, especially for females (Oliver 
et al, 2007), suggesting that female methadone-maintained 
†  Non-prescribed.
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clients who use alcohol may have an elevated risk of fatal 
overdose. The poor outcomes for alcohol consumption  
among women on the ROSIE study highlights a need for 
treatment services, in particular methadone service providers,  
to continuously assess and actively target drinking behaviour. 
Some improvements were observed in the physical and mental 
health complaints of ROSIE study participations at 1-year, but 
there were some gender variations in the extent of these 
changes. Men reported greater reductions in the frequency of 
anxiety and depression related health symptoms, despite there 
being no significant gender difference in the frequency of these 
symptoms at treatment intake. 
Reductions in offending behaviour were more marked for 
women than men. This gender difference in crime outcome 
may in part relate to differences in the pattern of criminal 
behaviour between men and women in the ROSIE sample. 
At treatment intake women were more likely than men 
to commit an acquisitive crime and less likely to report 
involvement in drug dealing. As in other studies the most 
commonly committed acquisitive crime was shop-lifting 
(Stewart et al, 2003). There were significant reductions in 
women’s involvement in both shoplifting and drug dealing  
at 1-year. 
Conversely, men reported a greater involvement in drug dealing 
at treatment intake. Although there was a significant reduction 
in reported drug dealing among men at 1-year, they remained 
more involved in dealing drugs than women. 
As in other studies, what is most striking are the similarities 
in outcomes for men and women on the ROSIE study, given 
the differences in their characteristics at treatment intake. 
The lack of association between pre-treatment gender 
differences in problems and treatment outcome has been 
described as the ‘gender paradox’ (Fiorentine et al, 1997). 
It is important that treatment programmes are able to 
respond to the needs of their client group. The extent to 
which treatment services in Ireland are actually tailored to 
the differing needs of men and women, as indicated by pre-
treatment characteristics, has yet to be explored. Nonetheless, 
the results of the ROSIE study are encouraging in that the 
men and women who participated reported substantial 
reductions in their drug use at 1-year. Some improvements 
were also observed in health related symptoms, and 
reductions in offending behaviour were reported.
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